ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

January 17, 2008 07:05 ET

ART Advanced Research Technologies Appoints Two Additional Sales Professionals to Lead North American Commercialization of Optix Imaging System

MONTREAL, QUEBEC--(Marketwire - Jan. 17, 2008) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that Mr. Matthew Smith, Ph.D., and Mr. Sean Pitts have joined the Company as Senior Area Sales Manager and Area Sales Manager respectively, for the North American preclinical imaging market segment.

Dr. Smith earned his Ph.D. from the University of Delaware, where his research focus was on nuclear magnetic resonance imaging (NMR) applied to biological systems. Prior to joining ART, he was Area Sales Manager at VisualSonics, Inc. and held sales management roles at Varian, Inc. and Chemagnetics, Inc., which provide him an excellent background to support imaging and high technology sales at ART. Dr. Smith will fulfill the role of Senior Area Sales Manager focusing his efforts in Eastern North America.

With over 12 years of top-level sales experience behind him, Mr. Pitts will lead the implementation of ART's commercial strategy in Western North America as well as oversee ART's channel development for preclinical imaging, in the Asia-Pacific region. Prior to joining ART, Mr. Pitts was Area Sales Manager for VisualSonics, Inc., a leader in ultrasound imaging, and has held various sales roles at Millipore Corporation and Stratagene, both leaders in their respective fields of research.

In late 2007, ART announced its intent to commercialize the Optix® preclinical imaging product portfolio direct in North America and Europe. "We are very pleased with our ability to recruit people of Matthew Smith's and Sean Pitts' caliber to the ART team. Their strong track record of selling imaging instrumentation and supporting a high technology user base gives us full confidence that they can represent the Optix product effectively in North America," said Sebastien Gignac, President and CEO of ART.

Dino DiCamillo, ART's Vice President of Global Sales and Marketing, Preclinical Imaging, added: "The appointment of Matthew Smith and Sean Pitts fulfills our obligation to ART's user base and enables the preclinical imaging team to execute our commercial strategy of distributing ART's preclinical molecular imaging solution direct to the customers in North America and Europe. It is our intention to provide world-class service and application assistance to enable our Optix users to fully utilize the potential of optical imaging in their research programs."

Dr. Smith commented: "I am very excited to take on this opportunity to execute on ART's commercial effort in preclinical imaging. My prior experience in helping build and develop a preclinical imaging business will translate well into the optical imaging field. I look forward to continuing to advance ART's market position and implement a successful team to support our customer base." Mr. Pitts added: "I am excited to join the ART commercial team. My career has afforded me the opportunity to participate in the commercialization of new and exciting technology and I see the same opportunity to develop molecular optical imaging at ART".

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed directly by ART and is used by industry and academic leaders worldwide. The SoftScan® optical breast imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing the SoftScan optical medical imaging device via a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. The distribution of the Fenestra line of imaging contrast agents is made through GE Healthcare Bio-Science KK in Japan and is sold directly by the Company in the rest of the world. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contact Information

  • ART Advanced Research Technologies Inc.
    Jacques Bedard
    Chief Financial Officer
    (514) 832-0777
    Email: jbedard@art.ca
    or
    ART Advanced Research Technologies Inc.
    Dino DiCamillo, Vice President of
    Global Sales & Marketing for Preclinical Imaging
    (514) 832-0777
    Email: ddicamil@art.ca
    Website: www.art.ca